This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BIIB031, recombinant Factor VIII, Long-Lasting Factor VIII, rFVIIIFc, Elocta (EU), efmoroctocog alfa
rFVIIIFc is a long-acting factor VIII fusion protein, consisting of a single molecule of Factor VIII attached to the constant region (Fc) of immunoglobulin G (IgG), in order to extend the half-life of this protein, and enable less frequent infusions. In the coagulation cascade, factor VIII acts as a cofactor for factor IXa in the activation of factor X.
Biovitrum and Syntonix
In January 2006, Biovitrum and Syntonix Pharmaceuticals entered into a co-development and commercialization agreement for Syntonix's long-acting, recombinant Factor IX, FIX:Fc. Under the terms of the agreement, Syntonix receives an initial collaboration fee and Biovitrum makes an equity investment in Syntonix. Biovitrum and Syntonix will jointly develop and commercialize FIX:Fc. Syntonix is responsible for marketing in North America and Biovitrum is responsible for marketing in Europe, Russia and the Middle East. The companies will equally share the costs and profits for development and commercialization of FIX:Fc. Under the terms of the agreement, Syntonix will receive milestone payments and an additional equity investment from Biovitrum based on the progress of the program. In the future, Biovitrum and Syntonix may decide to expand the collaboration to include additional long-acting protein products. Additional financial terms were not be...See full deal structure in Biomedtracker
Partners: Swedish Orphan Biovitrum UCB SA
Additional information available to subscribers only: